key: cord-0700204-sygqo0hi authors: Faltin, Kamil; Lewandowska, Zuzanna; Małecki, Paweł; Czyż, Krzysztof; Szafran, Emilia; Kowalska-Tupko, Agnieszka; Mania, Anna; Mazur-Melewska, Katarzyna; Jończyk-Potoczna, Katarzyna; Bobkowski, Waldemar; Figlerowicz, Magdalena title: SARS-CoV-2 attacks the weakest point - COVID-19 course in a pediatric patient with Friedreich's ataxia date: 2022-02-13 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.02.021 sha: dbc3d3410434f3e2bbcb7567ec9e9c90a06b9b58 doc_id: 700204 cord_uid: sygqo0hi COVID-19 pandemic is the biggest epidemiological problem of the 21st century. The severe course of SARS-CoV-2 infection in children is rare. Sometimes, especially in patients with chronic disease, COVID-19 may be insidious and life-threatening. This article presents the course of COVID-19 in a 17-year-old boy with Friedreich's ataxia-induced hypertrophic cardiomyopathy. Despite that the main symptoms of COVID-19 (i.e., fever, cough) were moderate at the beginning of the illness, the patient condition deteriorated rapidly due to cardiac problems, atrial fibrillation, and heart failure. He required antiarrhythmic treatment and pharmacological and electrical cardioversion. Moreover, because of pneumonia requiring supplemental oxygen, remdesivir and convalescent plasma therapy were utilized in this patient. For the patient recovery, the administration of the antiviral treatment was crucial. The most common symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children are fever, cough, and pharyngitis [Mania et al, 2021] . The severe course of COVID-19 infection in children (4-5%) [Cui et al, 2021] mainly affects patients with chronic diseases [Gallo et al, 2021] , especially cardiovascular, respiratory, and neurologic disorders [Tsabouri et al, 2021] . The virus entry point into the cell is angiotensinconverting enzyme 2 (ACE2). The tissues with the highest expression of the receptor may be more susceptible to damage [Muus C et al, 2021] . The infection may lead to the progression of neurodegenerative changes and dysfunction of the heart muscle [Zareef et al, 2020] . The current treatment of COVID-19 includes, among other medications, remdesivir [Shi et al, 2020] and convalescent plasma therapy [Małecki et al, 2021 ]. Friedreich's ataxia (FA), an autosomal recessive neurodegenerative disease, is the most commonly inherited ataxia. In 98% of cases, the disease is caused by a dynamic mutation in frataxin gene. Lowering the concentration of this protein leads to iron accumulation in the mitochondria, consequently, to cell damage. Typically, symptoms appear between the ages of eight and fifteen. In the course of the disease, degeneration occurs within the spinal-cerebellar tracts, posterior cords of the spinal cord, and the pyramidal pathways and cerebellum. The most common symptoms are ataxia and dysarthria. Limb weakness progresses, resulting in paresis and, subsequently, paralysis. Approximately 90% of patients develop cardiomyopathy (most often hypertrophic). The causal treatment is unknown [Pandolfo et al, 2008] . The presented case is a 17-year-old boy with hypertrophic cardiomyopathy (HCM) due to FA. One year before his admission to the hospital, accelerated ventricular rhythm episodes were recorded in the Holter monitoring (Table 1) . From then on, the boy was taking metoprolol (47.45 mg daily). The patient had other symptoms characteristic of the FA: limb ataxia, dysarthria, and paresis of the lower and upper limbs. Generalized muscle atrophy, underweight (BMI 15.4, .3), scoliosis and contractures of the lower limbs were visible. The first symptoms of infection in this patient were dry cough and fever (38.5 °C). He received azithromycin and supportive treatment. SARS-CoV-2 infection was confirmed by PCR test. Due to progressive weakness, the patient was referred to the hospital. The fever and intensive cough resolved by the time of admission. His oxygen saturation [SpO 2 ] was above 96%, while his heart rate remained at the level of 70-100/min. The alveolar murmur over the lung fields was muffled, with no additional sounds. The patient heart rate was stable. His capillary refill time was extended to 3s, but his other vital parameters were normal (blood pressure [BP] 103/67 mmHg; heart rate [HR] 90/min; SpO 2 96-97%;). Laboratory tests found out erythrocytosis (6.57x10 6 /μl; reference range: 4.5-5.5x10 6 /μl), thrombocytopenia (119x10 3 /μl; reference range: 150-400x10 3 /μl), elevated levels of troponin I (926.9 ng/l; upper limit of normal (ULN): <9ng/l), and brain natriuretic peptide (BNP) 184.9 pg/ml; ULN:<100ng/l). Inflammatory, gasometric analysis, coagulation and other biochemical parameters, as well as electrolyte concentrations, remained in the reference range. The patient chest X-ray did not show consolidation or pneumonic infiltrates. The electrocardiography (ECG) revealed left ventricular (LV) hypertrophy with secondary repolarization abnormalities (Table 1 ). Massive LV hypertrophy was confirmed by echocardiography; LV ejection fraction was 50%. We started administering ceftriaxone, dexamethasone, and enoxaparin (Table 1) . On the third day of hospitalization, oxygen therapy was started (4 l/min) due to the decrease in SpO 2 to 92%. The next day, during the oxygen withdrawal test, the saturation was 85%. Lung ultrasound showed a reduction in the severity of inflammatory lesions. During the patient hospitalization, no negative result of the SARS-CoV-2 PCR test were obtained. The boy was discharged home on the 17 th day of hospitalization. The echocardiogram performed one month later did not reveal any intensification of cardiomyopathy after SARS-CoV-2 infection. We did not observe in the patient any apparent psychological and cognitive sequelae of the COVID-19. Our patient presented typical symptoms during the first phase of the COVID-19, which were fever and cough. Apart from elevated troponin I and BNP levels, we found minor deviations in laboratory tests with no common abnormalities like leukopenia. CT revealed bilateral ground-glass opacification with the parenchymal densities consistent with viral pneumonia. The presented case, except for significantly increased myocardial damage parameters and ECG changes, could look like a typical course of COVID-19 [Cui X et al, 2021] . The patient with FA belonged to the risk group of severe courses of COVID-19 due to the cardiomyopathy with the history of arrhythmia episodes. During the COVID-19, the boy initially stable general condition collapsed sharply. AF is a commonly reported complication of HCM [Olivotto et al, 2001] and myocarditis [Canter CE et al, 2014] . Arrhythmias, associated with an increase in mortality, are a common occurrence in COVID-19 infections also in patients with no previous such episodes [Coromilas et al, 2021] . AF is significantly associated with an increased risk of unfavorable outcomes among COVID-19 patients [Yang H et al, 2021] . The findings of our patient were similar to that described in the fatal case report of SARS-CoV-2 infection in an 18-year-old girl with type 2 diabetes, metabolic syndrome, and hypertrophic cardiomyopathy [Simpson et al, 2020] . Rapid deterioration of health in both young patients could be related to the increased ACE2 expression in heart muscle that occurs in patients with hypertrophic cardiomyopathy. This mechanism may lead to an increase in viral replication [Bos et al, 2020] and myocardial damage. The role of iron deposits in the mitochondria, which are present in FA [Pandolfo, 2008] , and consequently the intensification of oxidative stress remains an open question. During COVID-19 in our patient, pharmacological and electrical cardioversion did not result in immediate rhythm control. The administration of available antiviral drugs: remdesivir and convalescent plasma had a significant effect on the stabilization of the patient's condition. It is possible that controlling viral replication may be crucial to the functioning of the heart. During SARS-CoV-2 infection, the organs affected by the chronic disease process are most susceptible to damage. COVID-19 in children with Friedreich's ataxia-induced hypertrophic cardiomyopathy can induce AF and heart failure. Rapid application of available anti-SARS-CoV-2 agents: remdesivir and convalescent plasma therapy are essential for good prognosis in COVID-19 cases. Marked up-regulation of ACE2 in hearts of patients with obstructive hypertrophic cardiomyopathy: implications for SARS-CoV-2-mediated COVID-19 Diagnosis and treatment of myocarditis in children in the current era Worldwide survey of COVID-19 associated arrhythmias A systematic review and metaanalysis of children with coronavirus disease 2019 (COVID-19) Predictors of COVID-19 severity: A literature review Wide spectrum of clinical picture of COVID-19 in children -From mild to severe disease Effects and safety of convalescent plasma administration in a group of polish pediatric patients with COVID-19: A case series Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy Friedreich ataxia Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis Coronavirus Disease 2019 Infection in Children with Pre-Existing Heart Disease Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review Meta-analysis of atrial fibrillation in patients with COVID-19 COVID-19 in Pediatric Patients: A Focus on CHD Patients ECG -electrocardiography; 3 Echo -echocardiography; 4 HR -heart rate; 5 bpm-beats per minute; 6 VPBs -ventricular premature beats; 7 LVH -left ventricular hypertrophy; 8 IVS -intraventricular septum; 9 LVPW -left ventricle posterior wall; 10 LVOTO -Left Ventricular Outflow Tract Obstruction; 11 LVEF -left ventricular ejection fraction SVPBs -supraventricular premature beats; 16 LVESD -left ventricular end-systolic diameter LVEDD -left ventricular end-diastolic diameter The authors declare no conflict of interests.